MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1823239 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.8%
TTM net income YoY45.8%
TTM EPS YoY47.6%
Revenue 3-yr CAGR-20.2%
Net income 3-yr CAGR—
Margins
Gross margin39.1%
Operating margin-45.4%
Net margin-30.8%
FCF margin-5.9%
EBITDA margin-35.1%
Returns
ROE-29.8%
ROA-9.1%
ROIC (approx.)-27.0%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets43.3%
Debt / equity0.75x
Current ratio4.66x
Interest coverage-4.57x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $185.74M | $259.19M |
| Cost of revenue | $151.75M | $150.88M |
| Gross profit | $33.99M | $108.31M |
| R&D expense | $17.40M | $19.22M |
| SG&A expense | $145.12M | $161.77M |
| Operating income | -$215.27M | -$235.62M |
| Interest expense | $26.99M | $47.70M |
| Pretax income | -$234.97M | -$261.48M |
| Income tax | -$4.21M | -$1.86M |
| Net income | -$130.77M | -$144.85M |
| EBITDA | -$191.71M | -$214.76M |
| EPS (basic) | -0.90 | -1.05 |
| EPS (diluted) | -0.90 | -1.05 |
| Weighted avg. shares (diluted) | 144.36M | 137.91M |
| Balance sheet | ||
| Cash & equivalents | $216.89M | $322.40M |
| Receivables | $25.50M | $38.52M |
| Inventory | $40.49M | $50.08M |
| Current assets | $296.25M | $429.15M |
| PP&E, net | $151.48M | $164.47M |
| Goodwill | $129.43M | $159.88M |
| Intangibles | $151.54M | $194.96M |
| Total assets | $770.58M | $1.01B |
| Current liabilities | $44.92M | $56.97M |
| Short-term debt | $5.44M | $5.44M |
| Long-term debt | $286.33M | $290.49M |
| Total debt | $291.77M | $295.93M |
| Total liabilities | $397.87M | $431.04M |
| Shareholders' equity | $212.38M | $325.29M |
| Net debt | $74.88M | -$26.47M |
| Cash flow statement | ||
| Operating cash flow | -$57.57M | $7.46M |
| Capital expenditure | $13.15M | $29.66M |
| Free cash flow | -$70.72M | -$22.19M |
| Investing cash flow | -$31.41M | -$24.32M |
| Financing cash flow | -$16.50M | -$235.71M |
| Depreciation & amortization | $23.56M | $20.85M |
| Stock-based compensation | $30.17M | $49.41M |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.